On February 1, 2022, the U.S. Department of Justice (DOJ) released its annual False Claims Act (FCA) enforcement statistics for fiscal year (FY) 2021.[1]

With collections amounting to $5.6 billion, FY 2021 marks DOJ’s largest annual total FCA recovery since FY 2014, and more than twice the $2.3 billion received in FY 2020. FY 2021 was also a record-shattering year for DOJ as it relates to health care fraud enforcement; over $5 billion (90% of the total) was obtained from cases pursued against individuals and entities in the health care and life sciences industries.


Largely due to blockbuster settlements with prescription opioid manufacturers (including a $2.8 billion resolution with one opioid manufacturer), DOJ recorded a record-shattering $5.1 billion in settlements and judgments, eclipsing the $1.9 billion recovered in FY 2020, from the health care industry.

Marking another record, DOJ’s health care recoveries in FY 2021 in non-qui tam actions ($3.6 billion) exceeded total qui tam recoveries, indeed, more than doubling that recovery ($1.5 billion).

DOJ’s press release specifically referenced recoveries in connection with specific health care enforcement priorities, including billing for unnecessary medical services, solicitation or payment of kickbacks to induce the purchase of goods or services paid for by federal health care programs, and risk adjustment fraud related to Medicare Advantage programs.


Whistleblowers (known as “relators” under the FCA) filed 598 new actions under the qui tam provisions of the FCA in FY 2021, a decrease from the 675 actions filed in FY 2020, and the lowest number of filings since FY 2010. Of the 598 qui tam cases filed in FY 2021, 388 were health care-related (65%), the lowest number of health care-related qui tam cases filed since FY 2010.

New FCA cases initiated by DOJ (known as “non-qui tam cases”) declined moderately in FY 2021, where DOJ filed 203 new cases as compared to 259 new cases in FY 2020.

Total awards to relators also fell in FY 2021 to the lowest number in over a decade. According to DOJ’s statistics, the government paid out $238 million to relators in FY 2021, the lowest number since FY 2008.


DOJ’s FY 2021 enforcement statistics also suggest increasing exposure in declined qui tam cases where relators pursue FCA cases without DOJ’s intervention. The $479 million collected in FY 2021 is the third largest in reported history and over double the recovery from FY 2020. As it relates to the health care and life sciences industries, the $452 million collected in FY 2021 is the largest recovery since FY 2015 and the second largest recovery in reported history.


Amidst the challenges associated with the ongoing COVID-19 pandemic, DOJ’s enforcement statistics demonstrate that enforcement activity has not wavered, especially as it relates to the health care and life sciences industries.

With a record-shattering year for DOJ recoveries stemming from enforcement against the health care and life sciences industries, regulated entities need to be increasingly diligent, both in ensuring comprehensive and effective compliance programs and in preparing to aggressively defend against any investigations and litigation that may arise out of government and qui tam-initiated fraud allegations.

*     *     *

[1] DOJ’s FY 2021 is for the period of October 1, 2020 to September 30, 2021.

Back to Health Law Advisor Blog

Search This Blog

Blog Editors


Related Services



Jump to Page


Sign up to receive an email notification when new Health Law Advisor posts are published:

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.